
|Articles|September 15, 2004
FDA advisory group likes Macugen but delays formal vote for now
New York-Members of the FDA's advisory committee reviewing pegaptanib sodium injection (Macugen) for the treatment of neovascular age-related macular degeneration say they are "impressed" with the drug but declined to take a formal vote.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Beyond the surface: Tackling complex dry eye cases
2
SpyGlass Pharma releases positive data from 2 trials of Bimatoprost Drug Pad-IOL System
3
Redefining glaucoma care: Where innovation meets clinical insight
4
Seborrheic dermatitis linked to multiple epithelial barrier diseases
5


















































.png)


